Neumora Therapeutics Inc Stock Price, News & Analysis

Neumora Therapeutics (Nasdaq: NMRA) will participate in two investor conferences in November 2025. Management will take part in fireside chats at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 2:30 p.m. ET in Boston and at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:00 p.m. ET in New York.

A live webcast of both events will be available on the company's events and presentations webpage at www.neumoratx.com, with replays archived for up to 30 days after the events.

Neumora Therapeutics (Nasdaq: NMRA) initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898 on Oct 27, 2025.

NMRA-898 is a structurally distinct second M4 muscarinic receptor positive allosteric modulator (PAM) alongside NMRA-861. Both programs aim for once-daily dosing and central nervous system exposure to treat schizophrenia and other neuropsychiatric disorders. Preclinical studies reported no convulsions across multiple species, including rabbits. The company will evaluate Phase 1 safety, tolerability, and human PK to decide whether to advance one or both programs and expects a comprehensive M4 franchise update by mid-2026.

Neumora Therapeutics (Nasdaq: NMRA) reported positive preclinical results for NMRA-215, an oral, brain-penetrant NLRP3 inhibitor for obesity. In three diet-induced obesity mouse studies, NMRA-215 produced up to 19% weight loss as a monotherapy and up to 26% weight loss in combination with semaglutide. The company plans to initiate a Phase 1 clinical study in Q1 2026. Additional data will be presented during a virtual R&D day on October 27, 2025 with a webcast and 30-day replay.

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, will host a virtual R&D Day on October 27, 2025, at 8:00 a.m. ET. The event will showcase the company's pipeline of seven programs targeting novel mechanisms for prevalent diseases.

Key presentations will feature NMRA-215, a brain-penetrant NLRP3 inhibitor for obesity treatment, NMRA-511 Phase 1b data for Alzheimer's agitation, the M4 franchise (NMRA-861 and NMRA-898), and navacaprant, a Phase 3 kappa opioid receptor antagonist.

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. The company, which focuses on developing therapeutics for prevalent diseases through seven distinct programs, will attend the Wells Fargo Healthcare Conference (Sept. 4), Morgan Stanley Global Healthcare Conference (Sept. 8), and H.C. Wainwright Global Investment Conference (Sept. 9).

Management will be available for one-on-one meetings at the Wells Fargo and Morgan Stanley events, while participating in a fireside chat at the H.C. Wainwright conference. The fireside chat will be webcast live and archived for 30 days on the company's website.

Neumora Therapeutics (NASDAQ: NMRA) reported Q2 2025 financial results and provided significant pipeline updates. The company ended Q2 with $217.6 million in cash, expected to fund operations into 2027. Key developments include initiating a Phase 1 SAD/MAD study for NMRA-861 in schizophrenia and prioritizing obesity as the lead indication for NMRA-215, their brain-penetrant NLRP3 inhibitor.

Financial results showed R&D expenses of $38.7 million (down from $48.6M in Q2 2024) and a net loss of $52.7 million (improved from $58.7M). The company anticipates six clinical data readouts over the next 18 months, including Phase 3 data for navacaprant in major depressive disorder and Phase 1b data for NMRA-511 in Alzheimer's disease agitation.

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, will host its Q2 2025 earnings call on August 6, 2025 at 4:30 p.m. ET. The company, which maintains a pipeline of seven brain disease programs including three in clinical stages, will present financial results and provide a business update.

The event will be accessible via webcast through the company's website at www.neumoratx.com, with a replay available for 30 days post-event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.

Neumora Therapeutics (Nasdaq: NMRA) has initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861, a highly potent and selective M4 positive allosteric modulator (PAM), in healthy adults and those with stable schizophrenia.

The drug candidate demonstrates potential best-in-class pharmacology and showed promising safety in pre-clinical studies with no convulsions observed across multiple species. The company expects to report Phase 1 data, including safety, tolerability, and pharmacokinetic results, in Q1 2026.

NMRA-861 aims to offer a differentiated treatment option for schizophrenia and other neuropsychiatric disorders, potentially providing improved therapeutic benefits compared to current antipsychotics and non-selective muscarinic agonists, with the possibility of once-daily dosing.

Neumora Therapeutics (NASDAQ: NMRA) reported its Q1 2025 financial results and provided key updates. The company secured a $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025. Their cash position stands at $249.4 million, extending runway into 2027. Q1 2025 saw a net loss of $68.0 million, with R&D expenses at $52.2 million and G&A expenses at $18.8 million. Key pipeline developments include: anticipated topline data for NMRA-511 in Alzheimer's disease agitation by end-2025, resumed enrollment for KOASTAL-3 and -2 studies with data expected in Q1 and Q2 2026 respectively, and plans to advance their M4 PAM program to clinical stage by mid-2025. The company is progressing with seven neuroscience programs targeting various neuropsychiatric disorders and neurodegenerative diseases.